Simulations Plus (SLP) Stock Price, News & Analysis

Company Overview

Simulations Plus, Inc. (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics. In addition to software sales, Simulations Plus offers consulting services, training and custom model development to support drug discovery and development projects from preclinical through clinical stages.

Founded in 1996 and headquartered in Lancaster, California, Simulations Plus has expanded its global footprint by serving clients across North America, Europe and Asia. The company’s software solutions are used by pharmaceutical and biotech firms, academic institutions and regulatory agencies to optimize formulation strategies, anticipate drug interactions and reduce the time and cost associated with in-lab or in-vivo studies. Over time, Simulations Plus has enhanced its product suite with modules for immunogenicity, absorption modeling and physiologically based pharmacokinetics, reflecting ongoing investment in research and development.

Under the leadership of founder and Chief Executive Officer Walter Woltosz, Simulations Plus maintains a focus on innovation and scientific rigor. The management team combines expertise in pharmacology, computational chemistry and engineering to deliver integrated solutions that help clients make data-driven decisions. By offering regular software updates, customer support and continuing education programs, the company seeks to stay at the forefront of modeling and simulation technologies for the life sciences sector.

Key Stats

• Today's Range: $18.31 to $18.34
• 50-Day Range: $15.88 to $18.39
• 52-Week Range: $11.09 to $21.01
• Volume: 151,224 shs
• Average Volume: 400,320 shs
• Market Capitalization: $370.41 million
• P/E Ratio: 45.78
• Dividend Yield: N/A
• Price Target: $17.25
• Consensus Rating: Reduce

Simulations Plus Stock Analysis - MarketRank™

Simulations Plus scored higher than 20% of companies evaluated by MarketBeat, and ranked 839th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Reduce

Consensus Rating

Simulations Plus has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no strong buy ratings, no buy ratings, 7 hold ratings, and 1 sell rating.

Downside Risk

Simulations Plus has a consensus price target of $17.25, representing about 5.8% downside from its current price of $18.31.

Amount of Analyst Coverage

Simulations Plus has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Simulations Plus is 45.78, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.70.

Price to Earnings Ratio vs. Sector

The P/E ratio of Simulations Plus is 45.78, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 269.68.

Price to Book Value per Share Ratio

Simulations Plus has a P/B Ratio of 2.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.38% of the float of Simulations Plus has been sold short.

Short Interest Ratio / Days to Cover

Simulations Plus has a short interest ratio ("days to cover") of 5.24.

Change versus previous month

Short interest in Simulations Plus has recently increased by 59.72%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Simulations Plus does not currently pay a dividend.

Dividend Growth

Simulations Plus does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Simulations Plus is 60.00%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.67

News Sentiment

Simulations Plus has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Simulations Plus this week, compared to 5 articles on an average week.

Search Interest

Only 3 people have searched for SLP on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Simulations Plus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $95,384.00 in company stock.

Percentage Held by Insiders

19.10% of the stock of Simulations Plus is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

78.08% of the stock of Simulations Plus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/09/2026
• Today: 8/13/2026
• Fiscal Year End: 8/31/2026
• Status update: 9/16/2026
• Next Earnings (Estimated): 10/29/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:SLP
• CIK: 1023459
• Web: www.simulations-plus.com
• Phone: (661) 723-7723
• Fax: 661-723-5524
• Employees: 160
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Simulations Plus: $17.25
• High Price Target: $18.50
• Low Price Target: $16.00
• Potential Upside/Downside: -5.8%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.40
• Trailing P/E Ratio: 45.78
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$64.72 million
• Net Margins: 9.88%
• Pretax Margin: 15.30%
• Return on Equity: 13.50%
• Return on Assets: 12.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.54
• Quick Ratio: 5.54

Sales & Book Value

• Annual Sales: $82.06 million
• Price / Sales: 4.51
• Cash Flow: $1.43 per share
• Price / Cash Flow: 12.79
• Book Value: $6.20 per share
• Price / Book: 2.95

Miscellaneous

• Outstanding Shares: 20,225,000
• Free Float: 16,362,000
• Market Cap: $370.32 million
• Optionable: Optionable
• Beta: 1.32